## Special Issue

# Cancer Stem Cells and Targeted Therapy

### Message from the Guest Editor

New scientific evidence is increasingly proving that cancer stem cells (or tumor-initiating cells) play a vital role in tumor initiation, development, progress and metastasis. They are also responsible for tumor recurrence and drug resistance. In addition, it is believed that they represent the origin of tumor heterogenicity. Therefore, they are an ideal target for cancer therapy and can eventually lead to the discovery of a cure. This Special Issue aims to publish/collect research on CSC biology and related therapies targeting CSCs, including establishing in vitro or in vivo studies and organoid models). Original research articles and reviews are invited for submission for the current Special Issue. Research areas may include (but are not limited to) the following: cancer stem cell biology (origin, development, distribution, migration, self-renewal, and differentiation): identification of biomarkers or therapeutic targets of CSCs (surface markers, signaling pathways, and gene markers); targeted therapies (with any drugs, such as chemo drugs, natural products, pathway inhibitors, and their delivery systems using nanotechnology). I look forward to receiving your contributions.

### **Guest Editor**

Dr. Wenyi Gu

Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD 4072, Australia

#### Deadline for manuscript submissions

closed (30 September 2024)



### Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/131534

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

